Thus, if targeting DcR3 is applied to clinic usage, inhibiting expression of DcR3 may inhibit tumor growth and promote tumor apoptosis, whereas increasing expression of DcR3 is expected to become a promising therapeutic method in autoimmune diseases (18). Here, TNFRSF6B is linked to autoimmune disease.